Asthma is characterized by airway inflammation and airway remodeling. Our previous study revealed that grape seed proanthocyanidin extract ( GSPE) could inhibit asthmatic airway inflammation and airway hyper-responsiveness by down-regulation of inducible nitric oxide synthase in a murine model of acute asthma . The present study aimed to evaluate GSPE's effects on airway inflammation and airway remodeling in a chronic asthmatic model. BALB/c mice were sensitized with ovalbumin (OVA) and then were challenged three times a week for 8 weeks. Airway responsiveness was measured at 24 h after the last OVA challenge. HE staining, PAS staining, and Masson staining were used to observe any airway inflammation in the lung tissue, airway mucus secretion, and subepithelial fibrosis , respectively. The cytokines levels in the lavage fluid (BALF) in addition to the total serum immunoglobulin E (IgE) levels were detected by ELISA. Furthermore, lung collagen contents, α-smooth muscle actin (α-SMA), and transforming growth factor-β1 (TGF-β1) expression in the airway were assessed by hydroxyproline assay, immunohistochemistry, and Western blot analysis, respectively .GSPE administration significantly suppressed airway resistance as well as reduced the amount of inflammatory cells, especially the eosinophil count, in BALF. Additionally, the GSPE treatment markedly decreased interleukin (IL) -4, IL-13, and vascular endothelial growth factor (VEGF) levels in BALF in addition to the total serum IgE levels. A histological examination demonstrated that GSPE significantly ameliorated allergen-induced lung eosinophilic inflammation and decreased PAS-positive epithelial cells in the airway . The elevated hydroxyproline contents , lung α-SMA contents, and TGF-β1 protein expression that were observed in the OVA mice were also inhibited by GSPE. In conclusion, GSPE could inhibit airway inflammation and airway remodeling in a murine model of chronic asthma , thus providing a potential treatment for asthma.
Asthma is an inflammatory disorder of the airways that is generally regarded as a reversible disease. However, this generality is not always the case; for example, numerous studies have demonstrated that lung function progressively deteriorates as this disease further develops. Furthermore, clinically, some asthmatic patients may even develop completely or incompletely irreversible airflow obstruction, even when they receive anti-inflammatory and bronchodilator therapy [1] . This is ascribed to the continuous damage that occurs in the airway as well as to secondary changes in the airway structure, also known as airway remodeling.
Airway remodeling is an important mechanism underlying the pathogenesis of asthma and is a basic airway pathophysiology of asthma. It involves airway smooth muscle cell hyperplasia and hypertrophy, deposition of extracellular matrix components, increases in the basement membrane, infiltration of inflammatory cells, glandular hyperplasia and hypertrophy, and angiogenesis [2] . Unfortunately, the precise mechanisms that underlie this airway remodeling remain unclear. However, it is known that a network of numerous inflammatory cells, endogenous airway cells, and inflammatory mediators and cytokines are involved in the pathogenesis of airway remodeling. Among these cytokines, transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) are two important growth factors [3] [4] .
Recently, plant extracts have been studied that have led to an increased awareness oftheir potential uses as drugs, such as polyphenols and flavonoids. An example of this is grape seed proanthocyanidin extract (GSPE), which is rich in polyphenols and condensed forms of catechin and epicatechin, in different amounts. Additionally, GSPE's anti-inflammatory and immunoregulatory effects have been confirmed in numerous studies on tumors, cardiovascular and cerebrovascular diseases, neurological diseases, and immune diseases, with promising results [5] [6] [7] [8] . Our previous study revealed that GSPE could inhibit airway inflammation and airway hyper-responsiveness (AHR) by down-regulating the inducible nitric oxide synthase (iNOS) in acute experimental asthma [9] . In addition, Mahmoud [10] found that grape seed extract significantly ameliorated airway remodeling of ovalbumininduced asthma and suggested the precise mechanism should be further elucidated. Thus, the present study was designed to evaluate the effects of GSPE on airway inflammation and airway remodeling, and to explore the possible mechanisms, in a mouse model of chronic asthma.
Lung function results showed that the RL values were comparable among the 4 groups at baseline. After challenge with Ach at different concentrations, the airway resistances in the OVA, BUD, and GSPE groups were significantly increased in a dose-dependent manner, whereas the control group showed only a slight increase (Figure1). After an administration of Achat 270 μg/mL, the airway resistance in the OVA group reached a maximum level and was significantly higher in comparison with the control group (P<0.01).GSPE administration exerted a sharp reduction in the elevated airway resistance.
The levels of IL-4, IL-13, and VEGF in BALF and total serum IgE in the OVA group were markedly increased in comparison with the control group (P<0.01). However, in contrast, in the OVA group, these levels were significantly reduced in the BUD and GSPE groups (P < 0.05). There were no differences between the BUD and GSPE groups ( Table 1) .
Few inflammatory cells were detected in the control group, except for macrophages. However, the total cells and eosinophil counts in BALF increased markedly after sensitization and challenge with OVA, which was followed by a significant decrease with either BUD or GSPE treatment ( Figure 2 ). Accordingly, an obvious infiltration of inflammatory cells into the peribronchiolar and perivascular connective tissues in the OVA group was observed, which was then noticeably reduced by either GSPE or BUD administration ( Figure 3 ). Furthermore, there was a dramatic increase in PAS positive epithelial cells in the small airways of the OVA group, which revealed goblet cell hyperplasia and mucus hypersecretion. Administering GSPE significantly reduced this suffering ( Figure 3 ). Thus, the preceding data clearly exhibit GSPE's inflammatory capabilities.
OVA sensitization and challenge resulted in either denser collagen deposition or fibrosis throughout the interstitium in the airways and blood vessels of tissues in comparison with the control group (P< 0.01). However, administering GSPE caused an overt reduction in collagen deposition. In contrast, there was no marked difference in the collagen areas between the BUD and GSPE groups (P > 0.05) ( Figure 4 ). Likewise, the total lung hydroxyproline content in the OVA group was significantly higher than that in the control group (P< 0.01). Treatment with GSPE significantly reduced the total lung hydroxyproline content ( Figure 4 ).The peribronchial α-SMA expression in the OVA group was significantly increased when compared with that in the control group (P<0.01). After being treated with either GSPE or BUD, the α-SMA expression was reduced compared with the OVA group (P < 0.05). However, there was no marked difference between the BUD and GSPE groups (P> 0.05) ( Figure 4 ).
Finally, we assessed TGF-β1 expression in the lungs to ascertain further whether TGF-β1 was related to the GSPE-induced antiairway remodeling effects. Western blot analysis was used to quantify the TGF-β1 expression ( Figure 5 ). The relative amount of targeted protein was quantified as the density of the targeted protein versus β-actin. After being normalized according to the β-actin protein expression, the relative density of TGF-β1 is presented as fold numbers. As demonstrated in Figure 5 , the elevated TGF-β1 expression that was observed in the OVA mice was significantly inhibited by GSPE. GSPE exhibited effects that were equal to those of BUD. In the present study, we successfully established a murine model of chronic asthma which manifested a characteristic infiltration of inflammatory cells in the airways, airway hyper-responsiveness, and airway remodeling after repeated OVA challenge. GSPE administration significantly inhibited the airway hyperresponsiveness, the airway inflammation (including an infiltration of inflammatory cells), expression of inflammatory cytokines, and mucus secretion, as well as airway remodeling in chronic asthmatic mice. To the best of our knowledge, this is the first time that GSPE's potential to inhibit airway remodeling in an OVA-induced model has been demonstrated. Furthermore, excessive IgE production is crucial during asthma development and is correlated to the disease's severity [12] . In both humans and rodents, increased IgE binds to IgE receptors on mast cells, which then facilitate the degranulation of the mast cells and the subsequent release of inflammatory mediators and cytokines. In addition, the infiltration of EOS in the airway is a pathological characteristic of asthma, and the accumulation of EOS is also crucial for the manifestation of airway remodeling. After this EOS activation, there is a release of massive amounts of cytokines and fiber growth factors (including TGF-β) that are involved in airway remodeling [13] . Our results showed that administration of GSPE profoundly reduced both the total serum IgE and total inflammatory cells, especially EOS, in BALF and in the peribronchiolar and perivascular connective tissues. Accordingly, these findings suggest that the immunoregulatory and anti-inflammatory effects of GSPE are beneficial for treating allergic diseases.
Aikawa et al. [14] reported that goblet cell hyperplasia with mucus accumulation in the airways of severe acute asthma attack was marked. Mucous gland hyperplasia is dependent on Th2-biased airway inflammation [15] ; this relationship is illustrated through the ability of airway mucus expression to be induced by the adoptive transfer of Th2 cells [16] and through the induction of goblet cell hyperplasia by Th2 cytokines (IL-4 and IL-13) [17] [18] . In addition, IL-4 and IL-13 are considered to bekey mediators of tissue fibrosis in the pathophysiology of asthma [19] . In the presence of IL-4 and IL-13, epithelial cells secret TGF-β, which in turn increases the secretion of matrix proteins and angiopoietin by myofibroblasts [20] . At the same time, IL-4 and IL-13 also facilitate the secretion of eotaxin by airway epithelial cells and sub-mucosal fibroblasts, which then recruit inflammatory cells, including EOS, into the airway and consequently results in the occurrence of asthma. In the present study, we demonstrated that GSPE treatment suppressed the mucus-producing goblet cells in the bronchiolar epithelium, deposition of subepithelial cells, and hydroxyproline content in the lung, in accordance with the decreased levels of IL-4 and IL-13 in BALF. Therefore, the ability of GSPE to inhibit Th2 cytokines, including IL-4 and IL-13, likely contributes to the reduction of mucus production and airway remodeling.
Some inflammatory cells and endogenous airway cells can secret
TGF-β1, which induces the transformation of fibroblasts into myofibroblasts [21] . Malmstorm et al. [22] found that there were significantly increased extracellular matrix contents in fibroblasts that were obtained from asthma patients and that TGF-β1 induced an excessive production of cytoskeletal proteins and cytoskeleton related proteins (such as actin and tropomyosin) in the fibroblasts, resulting in fibrosis. Thus, TGF-β1 may act on different cells and activate different signaling pathways that are involved in airway inflammation and airway remodeling. Moreover, blood vessel remodeling in chronic asthma is an important prerequisite feature of airway remodeling. VEGF is an important factor involved in angiogenesis and has also been found to be closely associated with chronic airway inflammation during airway remodeling in asthmatic patients [23] . More specifically, inhibiting VEGF production/secretion is likely to attenuate airway remodeling in asthma [24] . Our results showed that GSPE treatment remarkably reduced TGF-β1 expression in the lungs and VEGF expression in BALF of an asthmatic mouse model, in agreement with the inhibition of airway fibrosis. Therefore, the potential of GSPE to inhibit TGF-β1 and VEGF may be an important factor that could contribute to preventing airway remodeling in asthma.
The pathophysiology of AHR is complex because there are many factors that contribute to its development, including airway inflammation and airway remodeling. However, it is the latter that takes a more predominant role. In addition, airway remodeling has been linked to asthma severity and contributes to the development of AHR, which is due to the increase of smooth muscle mass in asthmatic airways [25] . It was reported that the amount of α-SMA significantly increased in animal models after chronic exposure to OVA [26] [27] .Our results confirmed this phenomenon. Moreover, we found that the OVA-induced increase in airway smooth muscle obviously decreased following GSPE treatment. Accordingly, as airway smooth muscle plays a critical role in AHR, the ability of GSPE to reduce the thickness of the airway smooth muscle layer may address its suppression of AHR.
Taken together, GSPE demonstrates noticeable potential in antiairway hyper-responsiveness, anti-airway inflammation, and antiairway remodeling in a chronic asthmatic model. However, injecting GSPE for the long term is not a convenient method, and it will be necessary to identify either another means of administering GSPE or to improve its absorption and bioavailability.
Nevertheless, GSPE is a promising medication for asthma treatment.
Experimental
Chemicals: GSPE was purchased from Jianfeng Inc. (Tianjin, China). Its ingredients were analyzed by gas chromatography-mass spectrometry in conjunction with high-performance liquid chromatography, the methods of which were detailed previously [9] .
Animals and experimental groups:
A total of 32 BALB/c female mice (specific pathogen free) aged 8 weeks and weighing 20 ± 2 g were provided by Shanghai SLAC Laboratory Animals Center (Shanghai, China). Mice were randomly divided into 4 groups: the control group, the asthma (OVA) group, the budesonide (BUD) group, and the GSPE group. The animals were housed at the Experimental Animal Center of Nanjing Medical University and treated according to a protocol which was approved by the Institutional Animal Care and Use Committee of Nanjing Medical University. The experimental protocol was approved by the Institutional Animal Ethics Committee (No. 2012026; Oct. 2012).
Antigen sensitization, challenge, and treatment:
The OVA, BUD, and GSPE groups were intraperitoneally injected with a sensitizing solution of 100μg OVA (Grade V; Sigma, St. Louis, MO, USA) that was emulsified in 1 mg aluminum hydroxide (Pierce Chemical Co., Rockford, IL, USA) with a total volume of 0.2 mL on days 0, 7, and 14. One week after the last sensitization, mice were challenged with 1% OVA by atomizing inhalation for 30 min/day, 3 times a week for 8 consecutive weeks. The OVA challenge was performed by aerosolizing OVA using an ultrasonic nebulizer (NE-U11B, Omuron, Tokyo, Japan)in a plexiglas box (29 cm ×22 cm × 18 cm).For the GSPE group, mice were intraperitoneally injected with GSPE that was dissolved in 0.9% sterile saline (50 mg.kg -1 .d -1 ) in a total volume of 0.2 mL solution for 8 consecutive weeks at 1 h before every OVA challenge. Alternatively, mice in the BUD group were treated with aerosolized BUD (2 mg/4 mL, AstraZeneca AB, Södertälje, Sweden) for 30 min at 1 h before every OVA challenge. As a control, mice were sensitized and challenged with an equivalent amount of 0.9% sterile saline instead of OVA.
Evaluation of airway responsiveness:
Evaluation of airway responsiveness to acetylcholine chloride (Ach) was performed by using an AniRes 2005 animal lung function analysis system (SYNOL High-Tech, Beijing, China), a process that was detailed in our previous study [9] .
Analysis of total serum IgE levels and bronchoalveolar lavage fluid (BALF):
Twenty-four h after the final OVA challenge, the mice were humanely sacrificed, and their blood was collected by retro-orbital puncture. Then, blood samples were centrifuged at 2000×g for 10 min at 4 o C, and the plasma was stored at -70 o C ready for testing. The airway lumina were washed 3 times with 0.4 mL PBS and BALF was collected. The total cell number in BALF was counted after the BALF was centrifuged (1000×gfor 10 min at 4°C). Cytospin techniques and Wright's staining were used for differential cell counting by counting at least 200 cells. Total serum IgE (BPB Biomedicals, Franklin, MA, USA),interleukin (IL)-4 (Jingmei Biotech, Shanghai, China), IL-13 (R&D Systems, Minneapolis, MN, USA), and VEGF (Jingmei Biotech, Shanghai, China) levels in BALF were measured with commercially available ELISA kits and were conducted according to the manufacturers' instructions. The lowest detection limits for IgE, IL-4, IL-13, and VEGF were 1 ng/mL, 7 pg/mL, 4 pg/mL, and 4 pg/mL, respectively.
Histological examination: After bronchoalveolar lavage, the upper lobe of the left lung was harvested, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned (5 μm) for haematoxylin-eosin (HE), periodic acid-Schiff (PAS), or Masson's trichrome staining. The histological analyses were performed by two pathologists who were blinded to the samples. Masson's trichrome staining was used to assess subepithelial fibrosis, and the results were expressed as the area of the trichrome staining per µm of the bronchioles' basement membrane length with an internal diameter of 150-200 µm by counting at least 10 bronchioles in each slide. We calculated the percentage of PAS-positive cells according to the number of PASpositive cells per bronchus divided by the total number of epithelial cells in each bronchiole, which quantified the level of mucus expression in the airway.
Hydroxyproline content measurement:
The total collagen content was determined by a hydroxyproline assay using a commercially available hydroxyproline detection kit (Nanjing Jiancheng Biotechnology, Nanjing, China). The frozen lower lobes of right lung tissues were homogenized by a Polytron tissue homogenizer in saline that contained 0.1 mol/L phenylmethylsulfonyl fluoride. The homogenized sample was hydrolyzed in 6 mol/L HCl, and the hydroxyproline concentration determined as previously described [11] .
Immunohistochemistry for α-smooth muscle actin (α-SMA):
The upper lobe of the left lung was harvested and prepared for sectioning as described above, followed by immunohistochemistry staining according to the manufacturers' instructions. Briefly, sections were deparaffinized with xylene and then rehydrated with graduated ethanol solutions. The endogenous peroxidase activity was blocked by incubating sections with 3% H 2 O 2 for 20 min, followed by subsequent boiling for 15 min for antigen retrieval. Thereafter, sections were blocked with 5% normal goat serum for 20 min at 37 o C, incubated with mouse anti-human α-SMA polyclonal antibody (Catalog number: N1584,DAKO, Glostrup, Denmark) overnight at 4 o C, a biotinylated secondary antibody for 30 min, and streptavidin horseradish peroxidase for 30 min, followed by staining with diaminobenzidine (DAB). The sections were counterstained with haematoxylin. For a negative control,the primary antibody was substituted with PBS. Three randomly selected bronchial rings (150-200 µm in diameter) were analyzed via a KS400 image analysis system (Ver. 3.0). Data are expressed as the area of α-SMA immunostaining per µmof length of the bronchioles' basement membrane.
Western blot analysis for TGF-β1:
In addition, 100 mg of frozen lung tissue was mixed with 600 μL of lysis buffer, followed by homogenization. The homogenate was kept at room temperature for1 h and then centrifuged at 20,000×g for 15 min at 4 o C. The supernatant was collected to determine the protein concentration. Then, 50 μg of protein was mixed with an equal volume of loading buffer and subjected to 12% polyacrylamide gel electrophoresis. Proteins were then transferred onto a polyvinylidene difluoride membrane that had been first incubated with a rabbit anti-mouse TGF-β1 polyclonal antibody (Catalog number: sc-146, Santa Cruz, CA, USA) and then an anti-β-actin polyclonal antibody (Catalog number: ab8227, Abcam, UK) for 1.5 h each. After washing the membrane, the proteins were visualized, and the protein bands were scanned. The optical density of the target protein to that of β-actin was determined.
Statistical analysis:
Data were expressed as the mean ± the standard error of the mean (SEM). The one-way analysis of variance (ANOVA) and the least significant difference (LSD) test were used to evaluate the differences. All calculations were carried out with SPSS software (SPSS 11.5, Chicago, IL, USA) and a 2-sided P value <0.05 was considered significant.
